News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.
This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025.
SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA"),
today announced it has enrolled the first subject for its Taiwanese clinical study of VELDONA®-based animal drug in treating feline chronic gingivostomatitis ("FCGS"), a serious and painful chronic cat oral disease characterized by inflammation or abnormal proliferation in the oral cavity. Dosing of the first subject is expected to occur on July 26, 2024.
This animal clinical study is a randomized, double-blind, parallel, single-center, multiple-dose oral drug trial designed to evaluate the safety, tolerability, and efficacy of low-dose oral interferons in the treatment of FCGS. The clinical site in Taiwan is expected to enroll 30 subjects.
This study builds on the animal health research of Ainos' VELDONA®, a low-dose oral interferon alpha ("IFNa") formulation that was initially approved by the Texas Department of Health in 1985 for treating feline leukemia in cats and canine parvovirus in dogs. The trial aims to complete the enrollment of 30 subjects by the end of 2024 and to finalize the trial report in the first quarter of 2025. If the results meet expectations, Ainos will initiate the next phase involving an application to a clinical field trial for an animal drug certificate from the Animal and Plant Health Inspection Agency under Taiwan's Ministry of Agriculture.
Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and CEO of Ainos, commented, "We are pleased to announce the enrollment of the first subject in the clinical trial, with dosing scheduled for July 26, 2024, marking an important milestone in the animal drug development process of VELDONA®. Initiating this clinical trial emphasizes our relentless efforts to advance innovative treatment options for cats with FCGS. Furthermore, we are also committed to fully leveraging our VELDONA® platform to develop a diversified portfolio of products for various therapeutic areas."
This strategic move comes as cat ownership in Taiwan is rising and outgrowing dog ownership. There are about 1.3 million domestic cats in Taiwan, a sharp increase of roughly 50% from 2021, according to data from Taiwan's Ministry of Agriculture. In addition to Taiwan, Ainos plans to actively working on capitalizing on larger market opportunities in other Asian markets and the U.S.
According to the 2023-2024 American Pet Products Association (APPA) National Pet Owners Survey, approximately 46.5 million U.S. households have pet cats. With an average of 1.78 cats per household, this results in a total of 82.8 million domestic cats. Given the prevalence rate of 0.7-10%, it is estimated that up to 8.3 million cats in the U.S. suffer from FCGS.
According to Grand View Research, the global market for pet dental health is projected to grow at a compound annual growth rate of 6.25% from 2023 to reach US$9.98 billion in 2030, driven by factors including increasing prevalence of pet dental diseases and rising awareness for preventing painful dental conditions in pets.
About VELDONA® Pet
Based on Ainos' low-dose oral interferon-alpha ("IFNa") formulation, VELDONA® Pet are supported by multiple research studies and clinical trials and are manufactured with world-class materials in a highly certified plant. VELDONA® Pet aims to maintain immunity in cats and dogs by contributing to gum and skin health for allergy relief and stress reduction. Interferon is a substance naturally produced by an organism's body. When cells are invaded by foreign particles, immune signaling molecules notify neighboring cells. Once neighboring cells receive the interferon's protein signal through their surface receptors, they initiate and modulate the immune system to protect felines and canines from gum and skin diseases, allergies, and stress-related conditions.
An earlier clinical study sponsored by Ainos and conducted by the Agricultural Technology Research Institute in Taiwan has demonstrated that VELDONA® Pet helps maintain the immune systems of cats and dogs. VELDONA® Pet not only aims to provide protection against common and hard-to-diagnose diseases including FCGS, a severe oral mucosal inflammatory disease afflicting cats, and canine atopic dermatitis (CAD), an inflammatory skin disease found in dogs, but also aims to offer safe and high quality products on the market.
About FCGS
FCGS is characterized by severe inflammation of the gingiva, buccal mucosa, and caudal oral mucosa. There are two types of FCGS. Type 1 includes cases with alveolar and labial/buccal mucositis/stomatitis only, while Type 2 covers caudal mucositis/stomatitis, with or without alveolar and labial/buccal mucositis/stomatitis. As of now, the exact causes of FCGS remains unknown. Cats with FCGS seemingly have a hyperimmune reaction to plaque, bacteria, viruses, or environmental factors to lead to excessive inflammation. FCGS is a common condition in cats, with a reported prevalence ranging from 0.7% to 12.0%.
Currently, medical management of FCGS remains highly variable and often depends on comorbidities in each individual case. Generally, existing medical therapies for FCGS include antibiotics, antihistamines, and immunosuppressants, such as corticosteroids or cyclosporine, which are often first-line treatments for affected animals. However, these immunosuppressants have serious long-term side effects, including type 2 diabetes and opportunistic infections. Currently, no medications exist for animals that are unresponsive to anti-inflammatory or immunosuppressive treatments, and there are no ideal long-term solutions available for pet owners.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and VELDONA low-dose interferon therapeutics. The Company's clinical-stage product pipeline includes VELDONA human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform.
The name "Ainos" is a combination of "AI" and "Nose" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https://www.ainos.com.
https://www.accesswire.com/891482/ainos-enrolls-first-subject-for-clinical-study-of-veldona-based-animal-fcgs-drug
With over 50 approved and pending patents, $AIMD Ainos is pioneering the AI Nose technology by seamlessly integrating AI deep learning with digital nose sensors for a new generation of rapid diagnostic tools designed for early, convenient and telehealth-friendly disease diagnosis and health monitoring. https://finance.yahoo.com/news/ainos-unveils-critical-progress-ainos-120000676.html
Next-Gen $AIMD Ainos Flora will advance with $NVDA NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trial kickoff
https://www.accesswire.com/877292/ainos-unveils-critical-progress-in-ainos-flora-clinical-trials-and-next-gen-plans-powered-by-nvidia-cuda
AIMD: Wake-up, you NOT-so-roaring-Kitty-Cat!!! LOOK ALIVE!!! Planet Earth needs Ladies with disease-free PUSSIES, for God's sake!!!!
PS: This post is so FUNNY, it could go 'VIRAL' across the Internet!!! (No pun intended, regarding the AIMD news today.)
AIMD: I'm losing my proverbial 'SHIRT on this sick puppy today, Dude --- SHOULD have listened to YOU!! HOWEVER, since I do like to mess-around with the 'LADIES' --- indeed, see me below right now, live --- therefore, it is commendable that the AIMD company is trying to FIX some issues with the 'private parts' of Planet Earth's HOT BLONDE CHICKS!!)
"Hey, Doll, go EASY on my hair piece!!"
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
$AIMD -Ainos | BREAKINGNEWS! Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA https://www.accesswire.com/877292/ainos-unveils-critical-progress-in-ainos-flora-clinical-trials-and-next-gen-plans-powered-by-nvidia-cuda
$AIMD HAS BIG NEWS COMING SOON... GET READY!
$AIMD The chart is poised for a perfect buy opportunity from here https://schrts.co/qCsPCgtF
$AIMD LOADING ZONE HERE! HEARING HUGE UPDATE COMING...
🔥 $AIMD HUGE BUYING OPPORTUNITY HERE!
— Stocks On High ALert💯 (@StockOnHighALer) June 11, 2024
🔥HEARING HUGE UPDATE COMING ...
🔥Ainos | AI + Nose Ainos, Inc.
🔥 Nasdaq: #AIMD @AinosInc @chazzsheen3 $DEGEN $GME $MNTC $LPA $DHAC $GNS $PTWO $IRAA $CTMX $FUFU $ADRT $MYSZ $TRSG $LXEH $MLGO $ZJYL $MNDR $GME $DTSS $OBLG $EDBL $ABVC pic.twitter.com/i91xmO6kmS
Ainos | AI + Nose $AIMD #NASDAQ -
Ever wonder this? Your tech gears have so many sensors inside: camera as eyes, microphone as ears and mouth, touch sensors behind the screen... Isn't it about time for your tech gears, or #AI, to have a nose? 🤔#GiveMeNose
Next week at COMPUTEX TAIPEI NVIDA , Supermicro , Intel Corporation , AMD will be in Taiwan for a big tech trade show. I assume there will be a lot of buzz about #Ai. $AI is driving a revolution that is rapidly reshaping every aspect of computing and the technology industry. Ainos | AI + Nose is on the forefront of this amazing technology.
computextaipei2024.com.tw/en/index.aspx
Ainos is a publicly traded company trading on the #NASDAQ
#AinosInc #AINOSE #AIMD #AIMD $AIMDW #SMCI #NVDA #AMD #QCOM #MSFT #INTC
AIMD under $2
$AIMD Chart from #DDAmanda - #1 Stock Screener :
Scans are preset. Push a Button. Find Winners Early:
Z
AIMD: See video-clip (below) of iHub's "Zorro" trader at a celebratory Wall Street PARTY last Friday!! (He always lands the best-lookin' CHICK!!)
AIMD: Why NOT??!! (Big PR news release looming!!)
These guys have it!!
https://marketchameleon.com/Reports/AfterHoursTrading
Should see a nice week next week looking forward to it 
$AIMD
Should see this flying next week, AI ticker and tons of shorts in this one to be squeezed hoping for a pop to $5+ chart is an absolute beauty 
$AIMD
|
Followers
|
26
|
Posters
|
|
|
Posts (Today)
|
1
|
Posts (Total)
|
617
|
|
Created
|
01/21/06
|
Type
|
Free
|
| Moderators | |||
AI
